Slowing COVID-19 Sales Will Drag On Roche In 2022

Growth To Be Flat Or Low Single Digit

 
• By Andrew McConaghie

Strong sales of COVID-19 diagnostics and therapies helped the Swiss company ride out the biosimilar attack in 2021, but it will not have the same buffer this year.  

Roche_Logo_Glass
2022 is also a big year for read-outs, including its Alzheimer's candidate gantenrumab. • Source: Alamy

More from Earnings

More from Business